

## Author's Response To Reviewer Comments

Close

Dear reviewer,

Thank you for your valuable comment. Our replies to the reviewer's inquiries and revised points are as follows. Please confirm the relevant parts highlighted in yellow in the revised manuscript. We realize some areas needed to be further elaborated. Therefore, we revised and added a few items in our methods and discussion section so readers can better understand our study. We hope this revision will provide sufficient explanation to your questions.

Reviewer #1:

1. Comment 1:

As a review, the article does not provide in-depth data that discuss treatment biases, such as tumor subtype, stage of cancer progression, and cellular target of chemotherapy.

Reply to comment 1:

We have revised accordingly, this stated on page 11-12 and 247-274

"Several risk factors affect the probability of chemoresistance. In studies, these factors potentially cause treatment bias."

2. Comment 2:

The correlations between overall clinical response and complete pathological response omit information that is relevant for a better understanding of therapeutic choices. Age, Tumor size, Differentiation, and other Clinical and pathological features are important for a better understanding of the initial data presented.

Reply to comment 2:

We have revised accordingly

3. Comment 3:

Tables 2 and 3 do not present clear information that provides answers to the discussion proposed in the study.

Reply to comment 3:

We have revised accordingly

4. Comment 4:

Tables 2 and 3 do not present clear information that provides answers to the discussion proposed in the study.

Reply to comment 4:

We have revised accordingly

5. Comment 5:

Current approaches to the role of hormone receptors, HER-2, and chemoresistance also quote mutations, heterogeneity gene expression and immune evasion.

Reply to comment 5:

We have revised accordingly

Reviewer #3:

1. Comment 1:

The author has been using abbreviation in the text like CAF, TA, TAC and many more without mentioning it's full terminology in the earlier part of the article. Please include the full terminology before using the abbreviation.

Reply to comment 1:

We have revised accordingly on the manuscript.

2. Comment 2:

The explanation and description given for each subheadings are incomplete and most of the time left the information hanging. Example, the last sentence under the subheading 'measurement of chemotherapy response', the author should write and explain more on the 5 levels of pathological response in the text and not only in the table.

Reply to comment 2:

We have revised accordingly on page 10-11, line 220-234.

"In the Miller-Payne system, pathologic response is divided into five grades based on comparison of tumor cellularity between pre-neoadjuvant therapy core biopsy specimens and definitive surgical specimens."

3. Comment 3:

Lack of continuity between one sub-heading to another.

Reply to comment 3:

We have revised accordingly

"The aim of this review was to provide a better insight into breast cancer response to chemotherapy."

"According to the data, the majority of the breast cancer patients who underwent chemotherapy had a partial response."

Chemotherapy resistance is an obstacle to treating neoplasms and compromises the choice of chemotherapy in cases of recurrence."

"Neoadjuvant chemotherapy has traditionally been used to treat locally advanced and initially inoperable breast cancer."

4. Comment 4:

Under the subheading 'suspected chemoresistance', the word 'decrease/disappearance' should be written as decrease or disappearance.

Reply to comment 4:

We have revised accordingly on page 11 line 239.

5. Comment 5:

The article was written in the very brief format as compare to extensive numbers of articles cited. A lot of missing information and require further description and explanation.

Reply to comment 5:

Thank you for your advice

Close



prihantono md &lt;prihantono.md@gmail.com&gt;

---

**Editor handles AMSU-D-21-00461R1**

1 message

**Annals of Medicine and Surgery** <em@editorialmanager.com>

Sun, Aug 29, 2021 at 1:38 AM

Reply-To: Annals of Medicine and Surgery &lt;annalsjournal@elsevier.com&gt;

To: Prihantono Prihantono &lt;prihantono.md@gmail.com&gt;

Ms. Ref. No.: AMSU-D-21-00461R1

Title: Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?

Annals of Medicine and Surgery

Dear Dr Prihantono,

Your submission "Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?" will be handled by Editor in Chief Riaz Agha.

You may check on the progress of your paper by logging on to the Editorial Manager as an author.

Thank you for submitting your work to this journal.

Kind regards,

Editorial Manager  
Annals of Medicine and Surgery

\*\*\*\*\*

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>

Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.



prihantono md &lt;prihantono.md@gmail.com&gt;

---

**Submission Confirmation for AMSU-D-21-00461R1**

1 message

**Annals of Medicine and Surgery** <em@editorialmanager.com>

Thu, Aug 26, 2021 at 9:16 PM

Reply-To: Annals of Medicine and Surgery &lt;annalsjournal@elsevier.com&gt;

To: Prihantono Prihantono &lt;prihantono.md@gmail.com&gt;

Ms. Ref. No.: AMSU-D-21-00461R1

Title: Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?

Annals of Medicine and Surgery

Dear Dr Prihantono,

This message is to acknowledge that we have received your revised manuscript for reconsideration for publication in Annals of Medicine and Surgery.

You may check the status of your manuscript by logging into the Editorial Manager as an author at

<https://www.editorialmanager.com/amsu/>.

Thank you for submitting your work to Annals of Medicine and Surgery.

Kind regards,

Editorial Manager  
Annals of Medicine and Surgery

\*\*\*\*\*

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.



prihantono md &lt;prihantono.md@gmail.com&gt;

---

## Your Submission

1 message

---

**Annals of Medicine and Surgery** <em@editorialmanager.com>

Fri, Sep 3, 2021 at 2:23 PM

Reply-To: Annals of Medicine and Surgery &lt;annalsjournal@elsevier.com&gt;

To: Prihantono Prihantono &lt;prihantono.md@gmail.com&gt;

Ms. Ref. No.: AMSU-D-21-00461R1

Title: Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?

Annals of Medicine and Surgery

Dear Dr Prihantono,

I am pleased to inform you that your paper "Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders.

In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal at <http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal>.

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

We appreciate and value your contribution to Annals of Medicine and Surgery. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

Jo Frankland  
Editorial Office  
Annals of Medicine and Surgery

Comments from the editors and reviewers:

\*\*\*\*\*

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.

**Date:** Sep 03, 2021  
**To:** "Prihantono Prihantono" prihantono.md@gmail.com  
**From:** "Annals of Medicine and Surgery" annalsjournal@elsevier.com  
**Subject:** Your Submission

Ms. Ref. No.: AMSU-D-21-00461R1

Title: Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?  
Annals of Medicine and Surgery

Dear Dr Prihantono,

I am pleased to inform you that your paper "Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it?" has been accepted for publication in Annals of Medicine and Surgery.

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders. In the next few days, you will be receiving information via email to allow you to choose one of the CC license options, providing funding information and a link to our payment system.

Learn about publishing Open Access in this journal at <http://www.elsevier.com/journals/Annals-of-Medicine-and-Surgery/2049-0801/open-access-journal>.

Your manuscript will be published online in raw form 4 days from this acceptance.

Below are comments from the editor and reviewers.

We appreciate and value your contribution to Annals of Medicine and Surgery. We regularly invite authors of recently published manuscript to participate in the peer review process. If you were not already part of the journal's reviewer pool, you have now been added to it. We look forward to your continued participation in our journal, and we hope you will consider us again for future submissions.

Yours sincerely,

Jo Frankland  
Editorial Office  
Annals of Medicine and Surgery

Comments from the editors and reviewers:

\*\*\*\*\*

For further assistance, please visit our customer support site at <http://help.elsevier.com/app/answers/list/p/7923>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EM via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/amsu/login.asp?a=r>). Please contact the publication office if you have any questions.